^
Association details:
| Biomarker: | HER-2 overexpression |
|---|---|
| Cancer: | Gastroesophageal Cancer |
| Drug: | zanidatamab (ZW25) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers.
Published date:
05/16/2018
Excerpt:
...efficacy in separate expansion cohorts, including HER2-high (IHC 3+ or 2+/FISH+) breast (BC), gastric/esophageal (GE)...33 pts have been treated in P1 and P2: 17 BC, 11 GE and 5 other cancers. HER2-high BC pts...ZW25 has been well tolerated with promising single agent anti-tumor activity in pts with heavily pretreated HER2-expressing cancers that have progressed after standard of care, including multiple HER2-targeted regimens.
DOI:
10.1200/JCO.2018.36.15_suppl.2500
Trial ID:
